比较多西他赛-铂类与多西他赛-铂类-5FU作为临界可切除口腔癌新辅助化疗的3期随机对照试验
这项3期随机优效性研究纳入495例临界可切除局部晚期口腔癌成人患者,1:1随机接受TP或TPF新辅助化疗2周期。TPF组5年总生存率23.9%优于TP组18.5%(HR 0.778,95%CI 0.637-0.952,P=0.015),但3级及以上不良事件更多(72.5% vs 39.1%,P<0.0001)。
要点
- TPF组5年OS为23.9%,TP组为18.5%,TPF较TP有生存获益(HR 0.778,P=0.015)。
- TPF组3级及以上不良事件发生率为72.5%,高于TP组的39.1%(P<0.0001)。
- 新辅助化疗后34.5%患者接受手术,手术者5年OS为50.7%,未手术者为5%(P<0.0001)。
核心结论
- 在临界可切除口腔癌中,TPF新辅助化疗较TP有生存获益,毒性增加但可控。
- 接受手术的患者获得相对较好且持续的生存。
研究设计与样本
- 3期随机优效性研究,成人临界可切除局部晚期口腔癌患者按1:1随机接受TP或TPF。
- 共495例患者随机,TP组248例,TPF组247例。
- 给予2周期新辅助化疗后,在多学科门诊评估并规划后续治疗。
- 主要终点为总生存(OS),次要终点为无进展生存(PFS)和不良事件。
主要发现
- TP组5年OS为18.5%(95%CI 13.8-23.7),TPF组为23.9%(95%CI 18.1-30.1),HR 0.778(95%CI 0.637-0.952),P=0.015。
- 新辅助化疗后43.8%被判定为可切除,34.5%实际接受手术。
- 新辅助化疗后接受手术者5年OS为50.7%(95%CI 41.5-59.1),未手术者为5%(95%CI 2.9-8.1),P<0.0001。
- TP组3级及以上不良事件97例(39.1%),TPF组179例(72.5%),P<0.0001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy (NACT) with TPF (docetaxel, cisplatin, and 5FU) is one of the treatment options in very locally advanced oral cancer with a survival advantage over PF (cisplatin and 5FU). TP (docetaxel and cisplatin) has shown promising results with a lower rate of adverse events but has never been compared to TPF. METHODS: In this phase 3 randomized superiority study, adult patients with borderline resectable locally advanced oral cancers were randomized in a 1:1 fashion to either TP or TPF. After the administration of 2 cycles, patients were evaluated in a multidisciplinary clinic and further treatment was planned. The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) and adverse events. RESULTS: 495 patients were randomized in this study, 248 patients in TP arm and 247 in TPF arm. The 5-year OS was 18.5% (95% CI 13.8-23.7) and 23.9% (95% CI 18.1-30.1) in TP and TPF arms, respectively (Hazard ratio 0.778; 95% CI 0.637-0.952; P = 0.015). Following NACT, 43.8% were deemed resectable, but 34.5% underwent surgery. The 5-year OS was 50.7% (95% CI 41.5-59.1) and 5% (95%CI 2.9-8.1), respectively, in the surgically resected versus unresected cohort post NACT (P < 0.0001). Grade 3 or above adverse events were seen in 97 (39.1%) and 179 (72.5%) patients in the TP and TPF arms, respectively (P < 0.0001). CONCLUSION: NACT with TPF has a survival benefit over TP in borderline resectable oral cancers, with an increase in toxicity which is manageable. Patients who undergo surgery achieve a relatively good, sustained survival.
引用
- Noronha V, Patil V, Chaturvedi P, et al. Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer. Eur J Cancer. 2024. PMID: 38306841. doi:10.1016/j.ejca.2024.113560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。